A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)

Conclusion The rapid change of the treatment landscape, the limited use of BEV/IFN in 1st line and the durati on of 1st line treatment jeopardized BERAT trial recruitment. The small number of patients is a major limitation of our trial. Our observation indicated the poor prognosis in progressive patients and the limited efficacy of TKI or mTOR inhbitors in 2nd line treatment.
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research